Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine effects on brain reward pathways in MDD
NCT02346539Phase 1Completed
- Sponsor
- McLean Hospital
- Start
- Feb 2015
- Primary completion
- Nov 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Nicotine with Placebo (2 arms). Primary endpoint: Change from Placebo in functional magnetic resonance imaging (fMRI) BOLD Response at 2 weeks. Started Feb 2015; status: completed.
02
Drugs
nicotine polacrilex
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02346539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346539.